1280786-83-5

Basic information

• Product Name: 5-Bromo-1-isopropylindazole
• Synonyms: 5-Bromo-1-isopropylindazole;5-Bromo-1-isopropyl-1H-indazole
• CAS NO: 1280786-83-5
• Molecular Formula: C10H11BrN2
• Molecular Weight: 239.11174
• Mol File: 1280786-83-5.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 5-Bromo-1-isopropylindazole(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Bromo-1-isopropylindazole(1280786-83-5)
• EPA Substance Registry System: 5-Bromo-1-isopropylindazole(1280786-83-5)

Safety Data

• Hazardous Substances Data: 1280786-83-5(Hazardous Substances Data)

Usage

General Description

5-Bromo-1-isopropylindazole is a chemical compound with the molecular formula C9H10BrN. It is a brominated derivative of 1-isopropylindazole, and it is commonly used as a building block in organic synthesis. 5-Bromo-1-isopropylindazole is known for its versatile reactivity and is used in the preparation of various pharmaceuticals and agrochemicals. It has also been studied for its potential biological activities, including its effects on serotonin receptors in the brain. Overall, 5-Bromo-1-isopropylindazole is a valuable chemical for the development of new drugs and chemical products.

Upstream product

• 75-30-9 2-iodo-propane 
• 53857-57-1 5-bromo-1H-indazole 
• 75-26-3 isopropyl bromide 

Relevant articles and documents

Discovery of (1 H-Pyrazolo[3,4- c]pyridin-5-yl)sulfonamide Analogues as Hepatitis B Virus Capsid Assembly Modulators by Conformation Constraint

Hepatitis B virus (HBV) capsid assembly modulators (CAMs) have been suggested to be effective anti-HBV agents in both preclinical and clinical studies. In addition to blocking HBV replication, CAMs could reduce the formation of covalently closed circular DNA (cccDNA), which accounts for the persistence of HBV infection. Here, we describe the discovery of (1H-indazole-5-yl)sulfonamides and (1H-pyrazolo[3,4-c]pyridin-5-yl)sulfonamides as new CAM chemotypes by constraining the conformation of the sulfamoylbenzamide derivatives. Lead optimization resulted in compound 56 with an EC50 value of 0.034 μM and good metabolic stability in mouse liver microsomes. To increase the solubility, the amino acid prodrug (65) and its citric acid salt (67) were prepared. Compound 67 dose dependently inhibited HBV replication in a hydrodynamic injection-based mouse model of HBV infection, while 56 did not show in vivo anti-HBV activity, likely owing to its suboptimal solubility. This class of compounds may serve as a starting point to develop novel anti-HBV drugs.

As a new polyphenylenepolymethylenepolyisocyanate deriv. SGLT2 inhibitor

A compound with a diphenylmethane moiety having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney is disclosed. A pharmaceutical composition including the compound as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes is disclosed. A method for preparing the compound, and a method for preventing or treating metabolic disorders, particularly diabetes, by using the compound is provided.